Pharos iBio Co., Ltd. Logo

Pharos iBio Co., Ltd.

AI-powered drug development for rare and refractory diseases, focusing on oncology.

388870 | KO

Overview

Corporate Details

ISIN(s):
KR7388870008
LEI:
Country:
South Korea
Address:
경기도 안양시 동안구 흥안대로427번길 38, 1408호(관양동, 성지스타위드), 안양시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Pharos iBio Co., Ltd. is a clinical-stage biotechnology company specializing in the development of novel drugs for rare and refractory diseases, with a particular focus on oncology. The company leverages its proprietary artificial intelligence (AI) and big data platform, Chemiverse®, to accelerate the drug discovery and development process. This platform integrates multiple modules, including protein structure analysis, to identify and optimize new drug candidates from target identification through to the preclinical stage. The company has successfully advanced its AI-developed therapies into clinical trials, notably for conditions like acute myeloid leukemia (AML), aiming to provide innovative treatments for patients with high unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-30 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (경구용 항암제 PHI101의 임상 1상 임상시험결과보고서(CSR) 수령)
Korean 14.4 KB
2025-06-26 00:00
Legal Proceedings Report
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (BRAF, KRAS 또는 NRAS 돌연변이를 가진 진행성…
Korean 15.8 KB
2025-06-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획승인신청등결정) (BRAF, KRAS 또는 NRAS 돌연변이를 가진 진행성 고형암 환…
Korean 12.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 956.3 KB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.3 KB
2025-03-25 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 18.2 KB
2025-03-18 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 364.5 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 173.4 KB
2025-03-05 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (BRAF, KRAS 또는 NRAS 돌연변이를 가진 진행성 고형암 환자를 …
Korean 9.3 KB
2025-02-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.2 KB
2024-12-20 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 18.2 KB

Automate Your Workflow. Get a real-time feed of all Pharos iBio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharos iBio Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharos iBio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.